These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 18929170)

  • 1. Cost-effectiveness.
    Lichter PR
    Ophthalmology; 2008 Oct; 115(10):1852-3; author reply 1853. PubMed ID: 18929170
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness.
    Brown GC; Brown MM
    Ophthalmology; 2008 Aug; 115(8):1433; author reply 1433-4. PubMed ID: 18675701
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost-effectiveness.
    Tuulonen A; Azuara-Blanco A
    Ophthalmology; 2009 Jan; 116(1):166-7; author reply 167. PubMed ID: 19118707
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost-effectiveness of treating ocular hypertension.
    Stewart WC; Stewart JA; Nasser QJ; Mychaskiw MA
    Ophthalmology; 2008 Jan; 115(1):94-8. PubMed ID: 18166406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of patients with ocular hypertension: a cost-effectiveness approach from the Ocular Hypertension Treatment Study.
    Rosenbaum LJ
    Am J Ophthalmol; 2007 Jan; 143(1):191-2; author reply 192-3. PubMed ID: 17188074
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical outcomes of glaucoma treatment over a patient lifetime: a Markov model (letter).
    Kymes S
    J Glaucoma; 2006 Oct; 15(5):471-2; author reply 472-3. PubMed ID: 16988613
    [No Abstract]   [Full Text] [Related]  

  • 7. Glaucoma: where to now?
    Taylor HR
    Ophthalmology; 2009 May; 116(5):821-2. PubMed ID: 19410940
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost-effectiveness of treating normal tension glaucoma.
    Li EY; Tham CC; Chi SC; Lam DS
    Invest Ophthalmol Vis Sci; 2013 May; 54(5):3394-9. PubMed ID: 23599342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glaucoma care cost-effectiveness.
    Hoskins HD
    Ophthalmology; 2009 May; 116(5):1016. PubMed ID: 19410965
    [No Abstract]   [Full Text] [Related]  

  • 10. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States.
    Rein DB; Wittenborn JS; Lee PP; Wirth KE; Sorensen SW; Hoerger TJ; Saaddine JB
    Ophthalmology; 2009 May; 116(5):823-32. PubMed ID: 19285730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The long term effectiveness and cost-effectiveness of initiating treatment for ocular hypertension.
    van Gestel A; Schouten JS; Beckers HJ; Severens JL; Hendrikse F; Webers CA
    Acta Ophthalmol; 2014 Sep; 92(6):513-23. PubMed ID: 24330516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An introduction to decision analysis in the economic evaluation of the prevention and treatment of vision-related diseases.
    Kymes SM
    Ophthalmic Epidemiol; 2008; 15(2):76-83. PubMed ID: 18432490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The increased cost of medical services for people diagnosed with primary open-angle glaucoma: a decision analytic approach.
    Kymes SM; Plotzke MR; Li JZ; Nichol MB; Wu J; Fain J
    Am J Ophthalmol; 2010 Jul; 150(1):74-81. PubMed ID: 20493465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicentre, retrospective study of resource utilization and costs associated with glaucoma management in France and Sweden.
    Lindblom B; Nordmann JP; Sellem E; Chen E; Gold R; Polland W; Williamson W; Buchholz P; Walt JG; Groleau D; Curry A; Evans SJ
    Acta Ophthalmol Scand; 2006 Feb; 84(1):74-83. PubMed ID: 16445443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of ocular hypertension: a cost-effectiveness approach from the Ocular Hypertension Treatment Study.
    Kymes SM; Kass MA; Anderson DR; Miller JP; Gordon MO;
    Am J Ophthalmol; 2006 Jun; 141(6):997-1008. PubMed ID: 16765666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness and cost utility of an organized screening programme for glaucoma.
    Vaahtoranta-Lehtonen H; Tuulonen A; Aronen P; Sintonen H; Suoranta L; Kovanen N; Linna M; Läärä E; Malmivaara A
    Acta Ophthalmol Scand; 2007 Aug; 85(5):508-18. PubMed ID: 17655612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of latanoprost and timolol maleate for the treatment of glaucoma in Scandinavia and the United Kingdom, using a decision-analytic health economic model.
    Stewart WC; Stewart JA; Mychaskiw MA
    Eye (Lond); 2009 Jan; 23(1):132-40. PubMed ID: 17721497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost-effectiveness of implementing a new guideline for cardiovascular risk management in primary care in the Netherlands.
    Kok L; Engelfriet P; Jacobs-van der Bruggen MA; Hoogenveen RT; Boshuizen HC; Verschuren MW
    Eur J Cardiovasc Prev Rehabil; 2009 Jun; 16(3):371-6. PubMed ID: 19305351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is primary trabeculectomy cost-effective for patients with advanced primary open angle glaucoma? Results from the Treatment of Advanced Glaucoma Study economic model.
    Shabaninejad H; Homer T; Kernohan A; King AJ; Burr J; Azuara-Blanco A; Vale L
    Br J Ophthalmol; 2024 Aug; 108(9):1210-1215. PubMed ID: 38336459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surveillance for ocular hypertension: an evidence synthesis and economic evaluation.
    Burr JM; Botello-Pinzon P; Takwoingi Y; Hernández R; Vazquez-Montes M; Elders A; Asaoka R; Banister K; van der Schoot J; Fraser C; King A; Lemij H; Sanders R; Vernon S; Tuulonen A; Kotecha A; Glasziou P; Garway-Heath D; Crabb D; Vale L; Azuara-Blanco A; Perera R; Ryan M; Deeks J; Cook J
    Health Technol Assess; 2012 Jun; 16(29):1-271, iii-iv. PubMed ID: 22687263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.